Bernstein Lifts UnitedHealth (UNH) Stock Price Target to $492 Amid Medicare Advantage Turnaround

Key Takeaways

• Bernstein SocGen Group upgraded UNH’s price target from $444 to $492 while maintaining an Outperform rating
• The updated target suggests approximately 27–30% potential upside based on UNH’s current trading price of $376.86
• Analyst projects 16% compound annual growth rate for adjusted earnings per share throughout the Medicare Advantage recovery period
• Firm increased target valuation multiple to 21.5x P/E from 20x, while UNH’s forward P/E expanded from 18.7x to 19.6x year-to-date
• Fourteen analysts have recently raised earnings projections, while Wall Street’s overall consensus remains Moderate Buy with a $397.05 average target

UnitedHealth Group (UNH) received a significant vote of confidence this Tuesday as Bernstein SocGen Group elevated its price objective for the healthcare giant to $492, up from the previous $444 target, while reaffirming its Outperform rating. Shares currently trade at $376.86.

UnitedHealth Group Incorporated, UNH

This revised target indicates potential gains of approximately 27% from present trading levels. Bernstein’s equity analyst Lance Wilkes highlighted strengthening Medicare Advantage fundamentals and an anticipated earnings rebound as the primary catalysts supporting the upgraded outlook.

UNH has faced considerable headwinds throughout the past year. Market participants have expressed concerns regarding escalating medical expenses and deteriorating profitability within the Medicare Advantage segment, placing downward pressure on the stock.

However, Wilkes believes a turning point has arrived. His analysis now anticipates adjusted earnings per share will expand at roughly 16% on an annual basis throughout the recovery trajectory — a growth rate he contends warrants an elevated valuation framework.

Factors Behind the Elevated Price Objective

Bernstein increased its target valuation multiple to 21.5 times earnings from the prior 20x benchmark. This remains modestly below UNH’s historical trading range during previous periods characterized by robust earnings expansion in the 13% to 16% range.

The stock’s forward price-to-earnings ratio has already demonstrated upward momentum. Beginning the year at 18.7x, it has subsequently advanced to 19.6x, indicating that certain market participants are already incorporating recovery expectations into their valuations.

Wilkes anticipates additional multiple expansion as market confidence in UNH’s sustainable long-term growth trajectory strengthens. According to InvestingPro, the company’s Fair Value stands at $472.26, reinforcing the assessment that shares remain undervalued at present levels.

The healthcare conglomerate commands a market capitalization of $342 billion and earns a “Good” financial health rating from InvestingPro. Fourteen equity analysts have recently revised their forward earnings projections upward.

Additional Developments at UnitedHealth

UNH has experienced several noteworthy developments beyond analyst coverage in recent months.

The company’s Optum Rx business unit recently unveiled a new transparent pharmacy benefit manager framework, transitioning to a fee-based compensation structure. This strategic shift aims to eliminate spread pricing practices and enhance cost predictability for pharmacy expenditures.

UnitedHealthcare has also disclosed plans to reduce prior authorization requirements for approximately 30% of healthcare services before the conclusion of 2026. This initiative encompasses specific outpatient surgical procedures and diagnostic evaluations.

On the regulatory front, UnitedHealth is navigating a temporary suspension on Medicare enrollments for new home healthcare and hospice service providers. The Trump administration’s anti-fraud taskforce implemented this moratorium to evaluate spending patterns and address fraud-related concerns.

The broader analyst community maintains cautiously optimistic sentiment. Among 23 analysts providing ratings over the past three months, 18 recommend Buy, four suggest Hold, and one advises Sell — translating to a Moderate Buy consensus perspective.

The average price objective across Wall Street stands at $397.05, suggesting modest 5.36% upside potential — significantly below Bernstein’s more optimistic $492 projection.

The post Bernstein Lifts UnitedHealth (UNH) Stock Price Target to $492 Amid Medicare Advantage Turnaround appeared first on Blockonomi.